1750 related articles for article (PubMed ID: 33177001)
1. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
2. Role of immunotherapy in bladder cancer.
Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
[TBL] [Abstract][Full Text] [Related]
3. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
4. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer.
Peyrottes A; Ouzaid I; Califano G; Hermieu JF; Xylinas E
Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440975
[No Abstract] [Full Text] [Related]
6. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.
Tayeh GA; Alkassis M; Semaan A; Khalil N; Nemr E; Waked C
Future Oncol; 2021 Sep; 17(25):3281-3283. PubMed ID: 34287018
[No Abstract] [Full Text] [Related]
8. Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?
Albisinni S; Aoun F; Diamand R; Mjaess G; Esperto F; Martinez Chanza N; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2020 Dec; 72(6):663-672. PubMed ID: 32993274
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy for muscle-invasive bladder cancer.
Jain RK; Sonpavde G
Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
11. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
[TBL] [Abstract][Full Text] [Related]
12. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
14. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
15. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S
Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213
[TBL] [Abstract][Full Text] [Related]
16. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.
Gust KM; Rebhan K; Resch I; Shariat SF; Necchi A
Curr Opin Urol; 2020 Jul; 30(4):547-556. PubMed ID: 32453001
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA; Sánchez AL; Spiess PE
Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
[TBL] [Abstract][Full Text] [Related]
19. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience.
Swami U; Grivas P; Pal SK; Agarwal N
Cancer Treat Res Commun; 2021; 27():100325. PubMed ID: 33549986
[TBL] [Abstract][Full Text] [Related]
20. Landmarks in the treatment of muscle-invasive bladder cancer.
Lobo N; Mount C; Omar K; Nair R; Thurairaja R; Khan MS
Nat Rev Urol; 2017 Sep; 14(9):565-574. PubMed ID: 28675174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]